focus -WSS

focus

author：Wikipedia 2025-10-01 17:05:38 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： The Harvard botanist who searched for psychedelics in the Amazon

explore

WSS

California’s proposed $25 per hour health care minimum wage

California’s proposed $25 per hour health care minimum wage

Lecanemab for Alzheimer's is coming. Is the health system ready?

New research casts further doubt on a common procedure used with IVF

It's time to get medical device identifiers over the finish line

STAT readers on older presidents, polypills, Medicare, and more

entertainment

focus

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Moonlake's readout produced a cash windfall. Risks remain

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Alkermes shareholders re

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

DIEP, the 'gold standard' of breast reconstruction, is under threat

Charles Manson follower Leslie Van Houten released from prison after 53 years

BioMarin wins approval for gene therapy to treat hemophilia A

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

focus

Dario to buy mental health app maker Twill in cash and stock deal

What to know about OceanGate, the company behind the missing Titanic submersible

A new study sees potential in DNA sequencing of infants

How the political right came to back psychedelics to treat trauma

Living with Fabry disease, a condition that causes chronic pain

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

leisure time

Wikipedia

explore

entertainment